Related Experiment Videos
[Lipid risk factors of atherosclerosis: who, when, how to treat?]
L Foubert1, S Dejager, E Bruckert
1Service d'Endocrinologie-Métabolisme, Hôpital de la Pitié, Paris.
Insights
High cholesterol and triglycerides increase cardiovascular disease risk. Effective lipid-lowering therapies, including diet, statins, and fibrates, reduce this risk, but Lp(a) remains challenging to treat.
Area of Science:
- Cardiology
- Metabolic Disorders
Context:
- Hyperlipidemia, specifically hypercholesterolemia, is a significant risk factor for cardiovascular disease (CVD), including coronary heart disease.
- Lipid-lowering therapies are crucial for both primary and secondary prevention of cardiovascular events, reducing morbidity and mortality.
Purpose:
- To outline the importance of precise lipid profiling before initiating treatment.
- To detail appropriate therapeutic strategies based on specific lipid patterns and cardiovascular risk factors.
Summary:
- Dietary modification is the foundational first step in managing hyperlipidemia.
- For hypercholesterolemia (Type IIa), cholestyramine and statins are primary treatments.
- Fibrates are the most effective agents for hypertriglyceridemia (Types IV and IIb), whether isolated or combined.
- Currently, no treatment effectively lowers lipoprotein(a) [Lp(a)] levels.
- Long-term adherence to lifelong treatment is essential for sustained cardiovascular risk reduction.
Impact:
- Informs clinical decision-making for personalized lipid management strategies.
- Highlights the role of pharmacotherapy in mitigating cardiovascular risks associated with dyslipidemia.
- Emphasizes the need for ongoing patient compliance for long-term health benefits.
Abstract:
Hyperlipidemia, particularly hypercholesterolemia, is a well established risk factor for cardiovascular disease, specially coronary heart disease. Lipid-lowering therapies are associated with a reduction in cardiovascular morbidity and mortality in secondary as well as primary prevention. A precise lipid pattern is necessary before any treatment. The target level depends on the clinical data and associated cardiovascular risk factors. Diet is the first step approach and should always be continued. Cholestyramine and statins are the treatments of choice in case of hypercholesterolemia (type IIa). In case of isolated or associated hypertriglyceridemia (types IV and IIb) fibrates are the most efficient. No treatment is really efficient on Lp(a) level. A good observance is required for a lifelong treatment.